Disitamab Vedotin (RC48-ADC)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Disitamab Vedotin (RC48-ADC), covering 2025-09-17 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 [Phase 2]